BR112022017267A2 - Métodos para tratar o câncer usando (r)-n-(3-fluoro-4-((3-((1-hidroxipropan-2-il) amino)-1h-pirazolo[3,4-b]piridin-4-il)óxi)fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetra-hidropirimidina-5-carboxamida - Google Patents

Métodos para tratar o câncer usando (r)-n-(3-fluoro-4-((3-((1-hidroxipropan-2-il) amino)-1h-pirazolo[3,4-b]piridin-4-il)óxi)fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetra-hidropirimidina-5-carboxamida

Info

Publication number
BR112022017267A2
BR112022017267A2 BR112022017267A BR112022017267A BR112022017267A2 BR 112022017267 A2 BR112022017267 A2 BR 112022017267A2 BR 112022017267 A BR112022017267 A BR 112022017267A BR 112022017267 A BR112022017267 A BR 112022017267A BR 112022017267 A2 BR112022017267 A2 BR 112022017267A2
Authority
BR
Brazil
Prior art keywords
tetrahydropyrmidine
hydroxypropan
dioxo
carboxamide
pyridin
Prior art date
Application number
BR112022017267A
Other languages
English (en)
Portuguese (pt)
Inventor
Sue Bouhana Karyn
Yuk-Fai Wong Jim
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of BR112022017267A2 publication Critical patent/BR112022017267A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112022017267A 2020-03-03 2021-03-01 Métodos para tratar o câncer usando (r)-n-(3-fluoro-4-((3-((1-hidroxipropan-2-il) amino)-1h-pirazolo[3,4-b]piridin-4-il)óxi)fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetra-hidropirimidina-5-carboxamida BR112022017267A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062984458P 2020-03-03 2020-03-03
US202163133501P 2021-01-04 2021-01-04
PCT/IB2021/051693 WO2021176330A1 (en) 2020-03-03 2021-03-01 Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

Publications (1)

Publication Number Publication Date
BR112022017267A2 true BR112022017267A2 (pt) 2022-12-13

Family

ID=74860342

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017267A BR112022017267A2 (pt) 2020-03-03 2021-03-01 Métodos para tratar o câncer usando (r)-n-(3-fluoro-4-((3-((1-hidroxipropan-2-il) amino)-1h-pirazolo[3,4-b]piridin-4-il)óxi)fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetra-hidropirimidina-5-carboxamida

Country Status (12)

Country Link
US (1) US20230117328A1 (enExample)
EP (1) EP4114397A1 (enExample)
JP (2) JP7181325B2 (enExample)
KR (1) KR20220148867A (enExample)
CN (1) CN115529816A (enExample)
AU (1) AU2021231435A1 (enExample)
BR (1) BR112022017267A2 (enExample)
CA (1) CA3174064A1 (enExample)
IL (1) IL296060A (enExample)
MX (1) MX2022010955A (enExample)
TW (2) TWI775333B (enExample)
WO (1) WO2021176330A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023002360A1 (en) * 2021-07-22 2023-01-26 Pfizer Inc. Solid forms and formulations of an inhibitor of tam and c-met kinases
CN122140719B (zh) * 2026-04-15 2026-07-28 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Sgi-7079在治疗flt3突变型急性髓系白血病中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US10195208B2 (en) * 2014-07-31 2019-02-05 Novartis Ag Combination therapy
WO2016019270A1 (en) 2014-07-31 2016-02-04 Academia Sinica An antagonistic pd-1 aptamer and its applications in cancer therapy related applications
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met

Also Published As

Publication number Publication date
CN115529816A (zh) 2022-12-27
TW202317125A (zh) 2023-05-01
JP2023009250A (ja) 2023-01-19
TWI814504B (zh) 2023-09-01
WO2021176330A1 (en) 2021-09-10
IL296060A (en) 2022-10-01
AU2021231435A1 (en) 2022-09-22
MX2022010955A (es) 2022-10-07
JP2021138693A (ja) 2021-09-16
EP4114397A1 (en) 2023-01-11
JP7181325B2 (ja) 2022-11-30
TWI775333B (zh) 2022-08-21
US20230117328A1 (en) 2023-04-20
TW202146025A (zh) 2021-12-16
CA3174064A1 (en) 2021-09-10
KR20220148867A (ko) 2022-11-07

Similar Documents

Publication Publication Date Title
BR112022008020A2 (pt) Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1
JOP20210319B1 (ar) مركبات بيروليدين
JOP20230277A1 (ar) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز (pi3k) لعلاج الأمراض
AR060089A1 (es) Tratamiento del dolor
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
JOP20210259A1 (ar) مستقبل استروجين يحلل خمير يستهدف التحلل البروتيني
BRPI0513565A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
EP2170876A4 (en) ISOXAZOLE DERIVATIVES PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF RESTENOSIS
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2014000130A (es) Procedimientos y composiciones para la inhibicion de resorcion osea.
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
BRPI0406674B8 (pt) composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de uma composição, dispositivo para pulverização, e, processo para preparar uma composição
BR112015030623A2 (pt) agentes citotóxicos para o tratamento de câncer
TN2020000161A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
MX2024011705A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica
MX2022010955A (es) Metodos para tratar el cancer usando (r)-n-(3-fluoro-4-((3- ((1-hidroxipropan-2-il)amino)-1h-pirazolo[3,4-b]piridin-4-il)oxi) fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetrahidro pirimidin-5-carboxamida.
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
BR112021024835A2 (pt) Tratamento para sinuclenopatias
BR112022022628A2 (pt) Inibidor de dhodh para o tratamento de covid-19
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
BR0317289A (pt) Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico
PL423672A1 (pl) Kompozycja farmaceutyczna zawierająca zebularynę oraz środek leczniczy do regeneracji ran
TW200509917A (en) Use of growth hormone secretagogues for treatment of fibromyalgia

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]